# Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

> **NCT02637973** · PHASE4 · COMPLETED · sponsor: **The Deutsche Diabetes Forschungsgesellschaft e.V.** · enrollment: 84 (actual)

## Conditions studied

- Type 2 Diabetes
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02637973
- **Lead sponsor:** The Deutsche Diabetes Forschungsgesellschaft e.V.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637973, "Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02637973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*